CD133/EpCAM Cancer Stem Cell Markers of Tumour Stage in Colorectal Cancer Cells
- Corresponding Author:
- BL Milner
Department of Internal Medicine
Faculty of Health Sciences, University of the Witwatersrand
7 York Road, Parktown, Johannesburg, South Africa 2193
Tel: +27 83 468 2145
E-mail: [email protected]
Received date: June 03, 2014;; Accepted date: November 25, 2014; Published date: November 28, 2014
Citation: Milner BL, Penny CB, Gibbon VE, Kay P, Ruff P (2015) CD133/EpCAM Cancer Stem Cell Markers of Tumour Stage in Colorectal Cancer Cells. J Tissue Sci Eng 6:143. doi:10.4172/2157-7552.1000143
Copyright: © 2015 Milner BL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In solid tumours, a discreet population of tumour associated cancer stem cells (CSCs) are proposed to drive and sustain tumour development and be responsible for tumour relapse. Colorectal cancer stem cells express cellspecific surface markers, including amongst others, CD133, EpCAM, CD44, CD166, and CD94f. In the present study, we aimed to characterisecellpopulations in the human colon adenocarcinoma cell lines, SW1116, HT29 and DLD1, expressing both CSC markers CD133 and EpCAM. These cell lines represent early, mid and late stages of colorectal tumours, respectively. Up to 107 SW1116, HT29 and DLD1 cells, co-stained with anti-CD133 and anti-EpCAM, were evaluated using flow cytometry. We report here progressive increasing proportions of cells coexpressing the CD133/EpCAM epitopes in the respective cell lines. In the SW1116 cell line, 2.42 ± 0.20 percent of cells were CD133+EpCAM+, in the HT29 cell line, 5.13 ± 0.17 percent of cells were CD133+EpCAM+, and in the DLD1 cell line, 10.30 ± 0.2 percent of cells were CD133+EpCAM+. These data suggest the frequency of CD133/ EpCAM marker expression may be associated with tumour stage and aggression.